 <h1>Pertuzumab Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><h2>In Summary</h2><p><b>Commonly reported side effects of pertuzumab include:</b> anaphylaxis, cytokine release syndrome, hypersensitivity condition, and infusion related reaction.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to pertuzumab: intravenous solution</i></p><h3>Warning</h3><p class="blackboxWarning-title">Intravenous route (Solution)</p><p>Pertuzumab can result in subclinical and clinical cardiac failure manifesting as decreased left ventricular ejection fraction and congestive heart failure. Evaluate cardiac function prior to and during treatment. Discontinue pertuzumab treatment for a confirmed clinically significant decrease in left ventricular function. Exposure to pertuzumab can result in embryo-fetal death and birth defects. Advise patients of these risks and the need for effective contraception.</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, pertuzumab may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<i>Check with your doctor or nurse immediately</i> if any of the following side effects occur while taking pertuzumab:</p><p>
<i>More common</i>
</p><ul>
<li>Black, tarry stools</li>
<li>burning, numbness, tingling, or painful sensations</li>
<li>chills</li>
<li>cough</li>
<li>fast heartbeat</li>
<li>fever</li>
<li>hives, itching, or rash</li>
<li>hoarseness</li>
<li>joint pain, stiffness, or swelling</li>
<li>lower back or side pain</li>
<li>painful or difficult urination</li>
<li>pale skin</li>
<li>redness of the skin</li>
<li>sore throat</li>
<li>swelling of the eyelids, face, lips, hands, or feet</li>
<li>tightness in the chest</li>
<li>troubled breathing or swallowing</li>
<li>ulcers, sores, or white spots in the mouth</li>
<li>unsteadiness or awkwardness</li>
<li>unusual bleeding or bruising</li>
<li>unusual tiredness or weakness</li>
<li>weakness in the arms, hands, legs, or feet</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of pertuzumab may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Body aches or pain</li>
<li>change in taste</li>
<li>cracked lips</li>
<li>decreased appetite</li>
<li>diarrhea</li>
<li>dizziness</li>
<li>dry skin</li>
<li>ear congestion</li>
<li>hair loss or thinning of the hair</li>
<li>headache</li>
<li>loosening of the fingernails</li>
<li>loss of taste</li>
<li>loss of voice</li>
<li>nasal congestion</li>
<li>nausea</li>
<li>redness or soreness around the fingernails</li>
<li>runny nose</li>
<li>sneezing</li>
<li>vomiting</li>
<li>watering of the eyes</li>
</ul><p>
<!-- end intravenous solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to pertuzumab: intravenous solution</i></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Left ventricular dysfunction (including congestive heart failure)<sup>[Ref]</sup></p><h3>Dermatologic</h3><p>Very Common (10% or more): Alopecia (61%), rash (34%), nail disorder (23%), pruritus (14%)</p>
<p><b>Common</b> (1% to 10%): Dry skin, palmar-plantar erythrodysesthesia syndrome<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Diarrhea (67%), nausea (42%), mucositis/mucosal inflammation (28%), constipation (25%), vomiting (24%), stomatitis (19%), dyspepsia (12%)<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Neutropenia (53%), anemia (23%), leucopenia (20%), febrile neutropenia (13%)<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Very common</b> (10% or more): Hypersensitivity/anaphylactic reaction, infusion reaction/cytokine release syndrome<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Decreased appetite (29%)<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Myalgia (24%), arthralgia (15%), pain in extremity (15%)<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Peripheral neuropathy (21%), headache (21%), dysgeusia (18%), peripheral sensory neuropathy (14%), dizziness (13%)<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Very common</b> (10% or more): Increased lacrimation (14%)<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Very common</b> (10% or more): Insomnia (13%)<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Cough (21%), upper respiratory tract infection (17%), dyspnea (16%), nasopharyngitis (13%)</p>
<p><b>Common</b> (1% to 10%): Paronychia, pleural effusion, epistaxis</p>
<p><b>Uncommon</b> (0.1% to 1%): Interstitial lung disease<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fatigue (38%), peripheral edema (30%), asthenia (30%), pyrexia (19%), pain</p>
<p><b>Common</b> (1% to 10%): Chills<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_2">2. "Product Information. Perjeta (pertuzumab)." Genentech, South San Francisco, CA. </p><p id="ref_3">3. Cerner Multum,  Inc. "Australian Product Information." O 0</p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>How long can you stay on Herceptin and Perjeta?</li>
<li>How much does Perjeta cost?</li>
<li>Is Perjeta a chemotherapy drug?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about pertuzumab</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Espa√±ol</li>
<li>Drug class: HER2 inhibitors</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Pertuzumab Intravenous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Perjeta</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Breast Cancer, Metastatic</li>
<li>Breast Cancer</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to pertuzumab: intravenous solution</i></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Left ventricular dysfunction (including congestive heart failure)<sup>[Ref]</sup></p><h3>Dermatologic</h3><p>Very Common (10% or more): Alopecia (61%), rash (34%), nail disorder (23%), pruritus (14%)</p><p><b>Common</b> (1% to 10%): Dry skin, palmar-plantar erythrodysesthesia syndrome<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Diarrhea (67%), nausea (42%), mucositis/mucosal inflammation (28%), constipation (25%), vomiting (24%), stomatitis (19%), dyspepsia (12%)<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Neutropenia (53%), anemia (23%), leucopenia (20%), febrile neutropenia (13%)<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Very common</b> (10% or more): Hypersensitivity/anaphylactic reaction, infusion reaction/cytokine release syndrome<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Decreased appetite (29%)<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Myalgia (24%), arthralgia (15%), pain in extremity (15%)<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Peripheral neuropathy (21%), headache (21%), dysgeusia (18%), peripheral sensory neuropathy (14%), dizziness (13%)<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Very common</b> (10% or more): Increased lacrimation (14%)<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Very common</b> (10% or more): Insomnia (13%)<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Cough (21%), upper respiratory tract infection (17%), dyspnea (16%), nasopharyngitis (13%)</p><p><b>Common</b> (1% to 10%): Paronychia, pleural effusion, epistaxis</p><p><b>Uncommon</b> (0.1% to 1%): Interstitial lung disease<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fatigue (38%), peripheral edema (30%), asthenia (30%), pyrexia (19%), pain</p><p><b>Common</b> (1% to 10%): Chills<sup>[Ref]</sup></p><p id="ref_1">1. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_2">2. "Product Information. Perjeta (pertuzumab)." Genentech, South San Francisco, CA. </p><p id="ref_3">3. Cerner Multum,  Inc. "Australian Product Information." O 0</p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>How long can you stay on Herceptin and Perjeta?</li>
<li>How much does Perjeta cost?</li>
<li>Is Perjeta a chemotherapy drug?</li>
</ul><h2>More about pertuzumab</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Espa√±ol</li>
<li>Drug class: HER2 inhibitors</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Pertuzumab Intravenous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Breast Cancer, Metastatic</li>
<li>Breast Cancer</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>